Enhabit (NYSE:EHAB – Get Rating) issued an update on its FY 2022 earnings guidance on Tuesday morning. The company provided earnings per share guidance of $1.37-$1.50 for the period, compared to the consensus earnings per share estimate of $1.56. The company issued revenue guidance of $1.07 billion-$1.08 billion, compared to the consensus revenue estimate of $1.09 billion.
Analyst Upgrades and Downgrades
EHAB has been the topic of several research reports. Jefferies Financial Group initiated coverage on Enhabit in a research report on Tuesday, August 30th. They issued a buy rating and a $20.00 target price on the stock. Credit Suisse Group reduced their price objective on Enhabit from $19.00 to $15.00 and set a neutral rating for the company in a research note on Friday. Bank of America began coverage on Enhabit in a research report on Wednesday, July 13th. They issued an underperform rating and a $16.00 target price on the stock. Citigroup began coverage on shares of Enhabit in a research report on Thursday, August 18th. They set a neutral rating and a $17.00 price target for the company. Finally, Oppenheimer initiated coverage on shares of Enhabit in a report on Thursday, October 13th. They issued a market perform rating on the stock. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of Hold and an average target price of $17.00.
Enhabit Stock Up 3.2 %
Enhabit stock opened at $13.05 on Tuesday. The business’s 50-day moving average is $14.31. The company has a current ratio of 1.50, a quick ratio of 1.41 and a debt-to-equity ratio of 0.63. Enhabit has a 52 week low of $11.65 and a 52 week high of $25.25.
Insiders Place Their Bets
In other news, Director Erin Hoeflinger purchased 6,030 shares of the stock in a transaction that occurred on Thursday, August 18th. The shares were purchased at an average cost of $13.62 per share, with a total value of $82,128.60. Following the completion of the acquisition, the director now owns 12,627 shares of the company’s stock, valued at approximately $171,979.74. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Enhabit news, Director Erin Hoeflinger bought 6,030 shares of the company’s stock in a transaction dated Thursday, August 18th. The shares were purchased at an average cost of $13.62 per share, for a total transaction of $82,128.60. Following the transaction, the director now directly owns 12,627 shares of the company’s stock, valued at $171,979.74. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Charles M. Elson purchased 3,700 shares of Enhabit stock in a transaction that occurred on Thursday, August 11th. The stock was acquired at an average cost of $13.55 per share, with a total value of $50,135.00. Following the acquisition, the director now directly owns 22,069 shares in the company, valued at approximately $299,034.95. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 11,442 shares of company stock worth $157,259.
Institutional Investors Weigh In On Enhabit
An institutional investor recently bought a new position in Enhabit stock. Millennium Management LLC bought a new stake in Enhabit, Inc. (NYSE:EHAB – Get Rating) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 10,000 shares of the company’s stock, valued at approximately $230,000. Institutional investors and hedge funds own 28.68% of the company’s stock.
Enhabit Company Profile
Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer’s disease, low vision, spinal stenosis, Parkinson’s disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Enhabit, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Enhabit wasn’t on the list.
While Enhabit currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
Techyrack Website stock market day trading and youtube monetization and adsense Approval
Adsense Arbitrage website traffic Get Adsense Approval Google Adsense Earnings Traffic Arbitrage YouTube Monetization YouTube Monetization, Watchtime and Subscribers Ready Monetized Autoblog
from NYSE Updates – My Blog https://ift.tt/uUWXaFc
via IFTTT
No comments:
Post a Comment